Recurrent pityriasis rosea: A case report

Pityriasis rosea is a papulosquamous skin disorder that occurs most commonly between the ages of 10 and 35 years. Recurrent pityriasis rosea is rare. We report a patient suffering from recurrent pityriasis rosea, whose etiology may be related to either vaccine-induced stimulation of the immune syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ang, Li, Ping, Li, Yanqiong, Li, Wenfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893202/
https://www.ncbi.nlm.nih.gov/pubmed/29182459
http://dx.doi.org/10.1080/21645515.2017.1409928
_version_ 1783313273939034112
author Li, Ang
Li, Ping
Li, Yanqiong
Li, Wenfei
author_facet Li, Ang
Li, Ping
Li, Yanqiong
Li, Wenfei
author_sort Li, Ang
collection PubMed
description Pityriasis rosea is a papulosquamous skin disorder that occurs most commonly between the ages of 10 and 35 years. Recurrent pityriasis rosea is rare. We report a patient suffering from recurrent pityriasis rosea, whose etiology may be related to either vaccine-induced stimulation of the immune system, or some rare vaccine component(influenza A [H1N1] vaccine, hepatitis B vaccine). We believe that such a case is unique and it has not been reported previously. The patient was successfully treated with a combination of oral cetirizine, a topical steroid cream, and narrowband-ultraviolet B phototherapy. The symptoms of this disorder should be recognized by dermatologists.
format Online
Article
Text
id pubmed-5893202
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-58932022018-04-13 Recurrent pityriasis rosea: A case report Li, Ang Li, Ping Li, Yanqiong Li, Wenfei Hum Vaccin Immunother Case Report Pityriasis rosea is a papulosquamous skin disorder that occurs most commonly between the ages of 10 and 35 years. Recurrent pityriasis rosea is rare. We report a patient suffering from recurrent pityriasis rosea, whose etiology may be related to either vaccine-induced stimulation of the immune system, or some rare vaccine component(influenza A [H1N1] vaccine, hepatitis B vaccine). We believe that such a case is unique and it has not been reported previously. The patient was successfully treated with a combination of oral cetirizine, a topical steroid cream, and narrowband-ultraviolet B phototherapy. The symptoms of this disorder should be recognized by dermatologists. Taylor & Francis 2017-12-21 /pmc/articles/PMC5893202/ /pubmed/29182459 http://dx.doi.org/10.1080/21645515.2017.1409928 Text en © 2018 The Author(s). Published with license by Taylor & Francis http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Li, Ang
Li, Ping
Li, Yanqiong
Li, Wenfei
Recurrent pityriasis rosea: A case report
title Recurrent pityriasis rosea: A case report
title_full Recurrent pityriasis rosea: A case report
title_fullStr Recurrent pityriasis rosea: A case report
title_full_unstemmed Recurrent pityriasis rosea: A case report
title_short Recurrent pityriasis rosea: A case report
title_sort recurrent pityriasis rosea: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893202/
https://www.ncbi.nlm.nih.gov/pubmed/29182459
http://dx.doi.org/10.1080/21645515.2017.1409928
work_keys_str_mv AT liang recurrentpityriasisroseaacasereport
AT liping recurrentpityriasisroseaacasereport
AT liyanqiong recurrentpityriasisroseaacasereport
AT liwenfei recurrentpityriasisroseaacasereport

Ejemplares similares